[ad_1]
Chemical derivatives of coffee could be used as medicine against Alzeihmer disease
REDUCTIONS, JULY 28 – Alzheimer's disease is the most serious form of dementia that causes progressive loss and inexorable memory. We, at the "window of rights", have intervened several times to point out the most significant discoveries, to give hope to all those who have received this diagnosis and their loved ones. The disease in question, as we know it, is characterized by a slow progressive decline of nerve cells and contacts between them. Therefore, it is a neurodegenerative pathology considered irreversible and for which no effective treatment is currently available. At least it was like that. But a promising new approach by researchers at the "Jean-Pierre Aubert Research Center" of the University of Lille in France, notes Giovanni D & # 39; Agata, president of the "Window of Rights", could change it. The first risk factor for Alzheimer's disease is aging. However, a combination of genetic and environmental factors also plays an important role. Coffee consumption has a particular impact on this risk. Coffee is the most consumed drink in the world after water. Coffee is also the main source of caffeine, which remains until today its most famous constituent. Caffeine is the most consumed psychoactive substance in the world. It is well known that it promotes attentive processes, excitement, information processing and, therefore, a significant impact on cognitive performance in humans and animals. Recent work also suggests a caffeine effect on memory processes and, in particular, on long-term memory, regardless of its attentional effects. This observation is related to several epidemiological studies suggesting that habitual consumption of caffeine reduces cognitive decline during aging. Other prospective studies also focus on the inverse relationship between caffeine consumption and the risk of developing Alzheimer's disease. The protective effects of caffeine would be optimal for doses of 3 to 4 cups a day. Interestingly, various experimental studies on animal models of Alzheimer's disease that mimic wounds and badociated memory disorders demonstrate a beneficial effect of caffeine at comparable doses, although the effects on behavioral symptoms have been recently discussed. The main targets of caffeine are the receptors called adenosine receptors. The effects of caffeine are particularly related to its ability to block one of these receptors called A2A adenosine receptor. A few years ago, our team demonstrated that the specific blocking of this receptor by genetic approaches and a chemical derivative of caffeine reduced memory disorders, neural communication disorders and Tau protein dysfunction in a model. . David Blum, research director Inserm at the University of Lille. In a new study, our team, working with colleagues from the University of Lisbon and Bonn, has shown that A2A adenosin receptor blockade of this caffeine derivative reduces amyloid lesions in the cortex and disorders Associated memory in an animal model reproduces amyloid plaques. This new study therefore suggests that caffeine-derived compounds targeting A2A adenosinergic receptors act positively on the two brain lesions characteristic of the disease. All of these observations suggest that the use of molecules derived from caffeine would be a therapeutic option in patients with Alzheimer's disease. It is very interesting to note that this type of molecule exists and has already been the subject of clinical studies in the context of Parkinson's disease. It is therefore possible and interesting to reposition these molecules in the therapeutic context of Alzheimer's disease. Before considering studies in humans, it is necessary to provide other convergent elements that reinforce the concept that it is important to block A2A receptors. These are the experimental studies that we are currently conducting. We hope to be able to define a clinical trial strategy in the next three to five years and raise funds for this purpose, concludes David Blum interview
Similar
[ad_2]
Source link
